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The anthracycline quinone doxorubicin (DOX;
adriamycin) is prescribed for the treatment of several
human tumors and leukemias. Despite its recognized
effectiveness against such neoplasias, the clinical success
of DOX is limited due to its dosedependent and cumula
tive cardiotoxicity [1]. DOX generates oxygen free radicals
as a consequence of undergoing redoxcycling on complex
I of the mitochondrial electron transport chain [2, 3], with
the resulting oxidative stress being implicated as a primary
cause of doxorubicininduced cardiac toxicity [4].
Mitochondrial oxidative damage and calcium overload,
both of which are associated with DOX toxicity [58], are
potent inducers of the mitochondrial permeability transi
tion (MPT) [9]. Consequently, the prooxidant nature of
DOX has been implicated as a primary cause for its toxic
ity. In fact, several authors have demonstrated that DOX
and its metabolites decrease the mitochondrial calcium
loading capacity that determines MPT pore opening, both
in vitro [10, 11] and in vivo [58]. The evidence clearly sug
gests that, by inducing the MPT, DOX interferes with
mitochondrial calcium regulation, which may be one of
the principal features in the pathogenesis of DOXinduced
cardiomyopathy. Furthermore, enhanced induction of the
MPT in heart mitochondria may also be responsible for
the decreased respiratory rates observed in heart mito
chondria isolated from DOXtreated animals [12].
The oxidation of specific thiol residues in mitochon
drial proteins has been described as a critical regulator of
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Abstract—Doxorubicin (DOX) is a highly effective treatment for several forms of cancer. However, clinical experience shows
that DOX induces a cumulative and dosedependent cardiomyopathy that has been ascribed to redoxcycling of the drug on
the mitochondrial respiratory chain generating free radicals and oxidative stress in the process. Mitochondrial dysfunction
including induction of the mitochondrial permeability transition (MPT) and inhibition of mitochondrial respiration have
been implicated as major determinants in the pathogenesis of DOX cardiotoxicity. The present work was aimed at investi
gating whether the inhibition of mitochondrial respiration occurs secondarily to MPT induction in heart mitochondria iso
lated from DOXtreated rats and whether one or both consequences of DOX treatment are related with oxidation of protein
thiol residues. DOXinduced oxidative stress was associated with the accumulation of products of lipid peroxidation and the
depletion of αtocopherol in cardiac mitochondrial membranes. No changes in mitochondrial coenzyme Q9 and Q10 con
centrations were detected in hearts of DOXtreated rats. Cardiac mitochondria from DOXtreated rats were more suscepti
ble to diamidedependent induction of the MPT. Although DOX treatment did not affect state 4 respiration, state 3 respi
ration was decreased in heart mitochondria isolated from DOXtreated rats, which was reversed in part by adding either
cyclosporin A or dithiothreitol, but not Trolox. The results suggest that in DOXtreated rats, (i) induction of the MPT is at
least in part responsible for decreased mitochondrial respiration, (ii) heart mitochondria are more susceptible to diamide
inducedMPT, (iii) thioldependent alteration of mitochondrial respiration is partially reversible ex vivo with dithiothreitol.
Collectively, these data are consistent with the thesis that thioldependent alteration of MPT and respiration is an impor
tant factor in DOXinduced mitochondrial dysfunction.
DOI: 10.1134/S000629790602012X
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MPT induction [13]. The protein containing critical thiol
residues has not been definitively identified, but was sug
gested to be the adenine nucleotide translocator (ANT)
[14]. The correlation between mitochondrial glutathione
and thiol redox status, induction of the MPT, and inhibi
tion of mitochondrial respiration suggests possible causal
relationships amongst these otherwise independent
events. However, it has yet to be demonstrated that oxida
tion of thiol groups caused by DOXinduced oxidative
stress [15] is causally related to rendering mitochondria
more susceptible to induction of the permeability transi
tion. Also, it remains to be determined if the inhibition of
mitochondrial respiration is a direct effect of DOX
induced thiol oxidation or if it is secondary to induction
of the MPT.
The present investigation was thus designed to assess
whether increased MPT induction caused by in vivo DOX
treatment is responsible for a secondary inhibition of state
3 respiration. We also investigated whether changed thiol
status impacts in regulating both altered MPT and respi
ration. The hypothesis was that cyclosporin A could revert
the inhibition of respiration observed in DOXtreated
animals. Also, heart mitochondria from DOXtreated
samples were suspected to be more susceptible to the
MPT induced by diamide, and that dithiothreitol (DTT),
as a thiol reducing agent, is able to restore normal mito
chondrial respiration.
MATERIALS AND METHODS
Chemicals. Ultrapure sucrose was obtained from
Schwarz/Mann Biotech (USA). DOX was purchased
from Pharmacia & Upjohn Co. (USA). Cyclosporin A
was a gift from Sandoz Pharmaceuticals (USA). All other
chemicals were of the highest grade available from Sigma
Chemical Co. (USA).
Animals and treatment protocol. Male Sprague–
Dawley rats (Harlan Labs, USA) weighing 200300 g were
maintained in AAALAC (Association for Assessment and
Accreditation of Animal Laboratory Care)accredited,
climatecontrolled facilities and allowed free access to
food (Purina Chow) and water. All studies were carried
out in accordance with the Guide for the Care and Use of
Laboratory Animals. Rats were randomly divided in two
experimental groups: saline (SAL)treated and DOX
treated. Rats received seven weekly subcutaneous (s.c.)
injections of either DOX (2 mg/kg) or an equivalent vol
ume of SAL solution (1 ml/kg). DOX dosage was estab
lished on the basis of previous studies that showed cardiac
mitochondrial damage and histopathology [6, 7]. The
animals were killed by decapitation one week after the last
injection and the hearts immediately excised to cold
buffer for mitochondrial isolation. Body and heart
weights were recorded on the day of the experiments. At
that time, DOXtreated rats had a lower heart (1.17 ±
0.09 versus 1.54 ± 0.06 g, p < 0.05, n = 10) and body
(287.3 ± 5.6 versus 386.6 ± 6.6 g, p < 0.05, n = 10) weight.
Isolation of cardiac mitochondria. Cardiac mito
chondria were prepared by differential centrifugation.
Briefly, the hearts were finely minced in an icecold isola
tion medium containing 250 mM sucrose, 1 mM EGTA,
10 mM HEPESKOH (pH 7.4), and 0.1% defatted
bovine serum albumin (BSA). The minced tissue was sus
pended in 40 ml of the isolation medium containing
0.5 mg protease type VIII (Sigma, P5390) per g of tissue
and homogenized with a tightly fitted homogenizer
(Teflon/glass). The suspension was incubated for 1 min
(4°C) and then rehomogenized. The homogenate was
then centrifuged at 9500g for 10 min. The supernatant
was decanted and the pellet was gently resuspended to its
original volume. The suspension was centrifuged at 900g
for 10 min, and the resulting supernatant was centrifuged
at 9000g for 10 min. This pellet was resuspended using a
brush and repelleted twice at 9000g for 10 min. EGTA
and defatted BSA were omitted from the final washing
medium. Mitochondrial protein content was determined
by the Bradford method calibrated with BSA [16]. The
yield of mitochondrial protein (mg protein/g heart tissue)
was not different between treatment groups (5.5 ± 0.5 for
SAL and 5.2 ± 0.2 for DOX group, n = 8).
Oxygen consumption. Oxygen consumption by iso
lated heart mitochondria was monitored polarographical
ly with a Clark oxygen electrode connected to a suitable
recorder. Reactions were carried out at 25°C in 1 ml of
media containing 100 mM KCl, 50 mM sucrose, 10 mM
TrisMops, 10 µM EGTA, and 2.5 mM KH2PO4
(pH 7.4). Mitochondria were suspended at a concentra
tion of 0.25 mg/ml in the respiratory medium. State 4 res
piration was measured in the presence of 5 mM gluta
mate/malate and ADP (210 nmol) was added to induce
state 3 respiration. The ADP/O was calculated according
to standard procedures [17]. Where indicated, Trolox
(100 µM), DTT (1 mM), and cyclosporin A (0.5 µM)
were added 3 min before mitochondrial energization.
Mitochondrial swelling. Mitochondrial volume
changes were estimated by monitoring changes in light
scattering measured at 540 nm. The assays were performed
in 1.5 ml of nonionic media composed of 200 mM
sucrose, 10 mM TrisMops, 10 µM EGTA, 5 mM
KH2PO4 (pH 7.4, 25°C), and 2 µM rotenone to which was
added 0.5 mg of mitochondrial protein. The incubation
medium is different from the one used for respiratory
experiments in order to provide better osmotic stability for
mitochondria. Succinate (4 mM) was added 2 min after
calcium addition (200 nmol CaCl2/mg protein). Diamide
concentrations ranging from 0.665 to 13.33 µM were
added 2 min after calcium addition. Initial rates of mito
chondrial swelling were measured for at least 3 min after
the onset of the decrease in absorbance. The time elapsed
between diamide addition and the beginning of the initial
decrease in the suspension absorbance was also recorded.
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Extraction and quantification of CoQ9, CoQ10, and
vitamin E. Aliquots of mitochondria containing 1 mg of
protein/ml were extracted according to the method
described by Takada et al. [18]. The extract was evaporat
ed to dryness under a stream of N2 and resuspended in
absolute ethanol. CoQ content was determined by
reversephase HPLC (Spherisorb RP18, S5ODS2 col
umn). Samples were eluted with methanol–heptane (10 :
2 v/v) at a flow rate of 2 ml/min. Detection was per
formed by an ultraviolet (UV) detector at 269 nm.
Vitamin E was extracted and quantified by following the
method described by Takayanagi et al. [19]. The extract
was evaporated to dryness under a stream of N2 and resus
pended in nhexane. Vitamin E content was determined
by reversephase HPLC (4.6 × 200 mm; Spherisorb S10w
column). Samples were eluted with nhexane supple
mented with 0.9% methanol at a flow rate of 1.5 ml/min.
Detection was performed by a UV detector at 287 nm.
Thiobarbituric acidreactive substances (TBARS)
determination. TBARS content in mitochondrial samples
was measured by HPLC according to Wong et al. [20].
Liquid chromatography was performed using Gilson
(USA) HPLC apparatus with a reverse phase column
(RP18, S5 ODS2). The samples were eluted from the col
umn at a flow rate of 1 ml/min and detection was per
formed at 532 nm. The TBARS content in the samples
was calculated from the standard curve prepared using
the thiobarbituric–malonyldialdehyde complex and
expressed in nmol/mg protein.
Statistical analysis. The results are presented as
mean ± SEM of at least five independent experiments.
Statistical comparison between selected experimental
groups was performed by using Student’s paired t test or
paired ANOVA, followed by Bonferroni’s posttest. A p <
0.05 was considered statistically significant.
RESULTS
In our model for in vivo DOXinduced mitochon
drionopathy, oxidative stress to mitochondrial samples
was confirmed on the basis of drugrelated changes in
thiobarbituric acidreactive substances (TBARS) and
vitamin E and coenzyme Q content as quantified by
highperformance liquid chromatography. Despite no
changes in the mitochondrial content of coenzymes Q9
and Q10, DOX treatment resulted in a 35% increase in
cardiac TBARS and a 25% decrease in vitamin E content
(table).
Diamide, which is known to promote thiol cross
linking [21], was used to titrate the rate of mitochondrial
swelling in the presence of calcium in order to assess
treatmentrelated alterations in the thioldependent reg
ulation of the MPT complex, as described previously [13,
21]. The rational behind this protocol is that oxidation of
thiol groups in critical elements of the MPT pore com
plex would be manifested as a susceptibility to diamide.
Mitochondrial swelling in both saline and DOXtreated
animals demonstrated biphasic kinetics (Fig. 1a).
Swelling curves in the presence of 13 µM diamide showed
that mitochondria from DOXtreated animals displayed a
shorter lag phase when compared with the corresponding
control (9.8 ± 0.5 versus 12.6 ± 0.9 min, p < 0.05, n = 4).
Furthermore, the rate of swelling with increasing concen
trations of diamide was significantly greater in cardiac
mitochondria isolated from DOXtreated animals com
pared to cardiac mitochondria isolated from salinetreat
ed control rats (Fig. 1b). In particular, for the highest
diamide concentration (13 µM), swelling rates were
0.0197 ± 0.0018 optical density unit per min for the DOX
group compared to 0.0123 ± 0.0023 optical density unit
per min for samples from saline treated rats (p < 0.05, n =
4) (Fig. 1b).
Treatment of rats in vivo with DOX resulted in a sta
tistically significant inhibition of state 3 respiration for
cardiac mitochondria (Fig. 2b), whereas there was no
treatmentrelated effect on state 4 respiration (Fig. 2a).
Although not shown, there was no treatmentrelated dif
ference in the phosphorylation efficiency of cardiac
mitochondria isolated from DOX compared to saline
treated rats (ADP/O ratio was 2.7 ± 0.1 versus 2.8 ± 0.2,
respectively, n = 7), which is in accordance with previ
ously published results [12]. Glutamate/malate was the
substrate used in the experimental protocol as previous
works showed a stronger inhibition of respiration by DOX
when using this substrate [12]. The DOXinduced inhibi
tion of cardiac mitochondrial state 3 respiration was par
tially reversed by both DTT and cyclosporin A. DTT by
itself, however, exhibited a direct inhibition of state 3 res
piration in cardiac mitochondria from salinetreated
rats.
Experimental
group
Coenzyme Q9
(pmol/mg protein)
Coenzyme Q10
(pmol/mg protein)
TBARS
(nmol/mg protein)
Vitamin E
(nmol/mg protein)
Control
(saline)
8573.3 ± 298.3
333.0 ± 16.5
1.61 ± 0.22
0.55 ± 0.06
DOX
8827.8 ± 588.0
335.6 ± 37.7
2.19 ± 0.18*
0.41 ± 0.04*
Levels of coenzyme Q9, coenzyme Q10, vitamin E, and
malonyldialdehyde in heart mitochondria isolated from
saline and DOXinjected animals (values are means ±
SEM of seven different mitochondrial samples; * p < 0.05
versus saline control)
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DISCUSSION
The widely described effect of DOX to generate oxy
gen free radicals and cause generalized oxidative stress
was evidenced by the loss of vitamin E and accumulation
of products of lipid peroxidation (TBARS) in cardiac tis
sue from drugtreated rats. The results are consistent with
previous reports that DOX causes oxidative stress in heart
mitochondria [15, 22], although no changes in the levels
of coenzyme Q9 and Q10 were observed. The hypothesis of
the present investigation was that the increased cardiac
MPT observed in DOXtreated rats is at least in part
responsible for the inhibition of respiratory function in
cardiac mitochondria. Also, our secondary hypothesis
was that DOXinduced oxidation of thiol residues in
mitochondrial proteins [15, 22] is responsible not only for
altering the MPT sensitivity to calcium and thioltarget
ed agents, but also for the effects of in vivo DOX treat
ment on mitochondrial respiration. Diamide and DTT,
two thiol specific agents, were used ex vivo to demonstrate
that thiol redox status is changed in cardiac mitochondria
from DOXtreated rats, which may be partially responsi
ble for the altered mitochondrial bioenergetics and open
ing of the MPT pore.
Fig. 2. Mitochondrial oxygen consumption during state 4 (a) or
state 3 (b) respiration in the presence of DTT (1 mM), Trolox
(100 µM), and cyclosporin A (Cycl.A, 0.5 µM). Reactions were
carried out at 25°C in 1 ml of media containing 100 mM KCl,
50 mM sucrose, 10 mM TrisMops, 10 µM EGTA, and 2.5 mM
KH2PO4 (pH 7.4). Mitochondria were suspended at a concentra
tion of 0.25 mg/ml in the respiratory medium. State 4 respiration
was measured in the presence of 5 mM glutamate/malate, and
ADP (210 nmol) was added to induce state 3 respiration. Where
indicated, DTT (1 mM), Trolox (100 µM), and cyclosporin A
(0.5 µM) were added 3 min before mitochondrial energization.
Cardiac mitochondria were isolated from saline (filled bars) or
DOXtreated (open bars) rats. The values are means ± SEM, n =
6; * p < 0.05 versus saline without additions; ** p < 0.05 versus
DOX without additions.
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Fig. 1. a) Typical recording of mitochondrial swelling induced by
calcium and diamide (13 µM) in heart mitochondria from DOX
or salinetreated rats. Mitochondrial swelling was followed by the
variation of absorbance at 540 nm. The assays were performed in
1.5 ml of a nonionic media composed of 200 mM sucrose,
10 mM TrisMops, 10 µM EGTA, 5 mM KH2PO4 (pH 7.4, 25°C),
and 2 µM rotenone to which was added 0.5 mg of mitochondrial
protein. Mitochondria were energized with 4 mM succinate.
Diamide concentrations ranging from 0.665 to 13.33 µM were
added 2 min after calcium (200 nmol CaCl2/mg protein) addition.
The recording is typical of four different preparations. b) The ini
tial rate of mitochondrial swelling induced by calcium in the pres
ence of diamide in heart mitochondria from saline and DOX
treated rats. The rates expressed in the graph were recorded in the
initial phase of the absorbance decrease as described in “Materials
and Methods”. The values are means ± SEM, * p < 0.05 versus
saline, n = 4.
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In fact, the results indicate that heart mitochondria
isolated from DOXtreated rats were more susceptible to
ex vivo diamideinduced swelling. Diamide, a bifunction
al thiol cross linking agent [21], increases the probability
for pore opening due to oxidation of protein thiol sites
that are in equilibrium with the mitochondrial pool of
pyridine nucleotides and reduced glutathione [13].
Although the specific regulatory protein has not been
conclusively identified, it has been suggested that the ade
nine nucleotide translocator (ANT) is a major target for
thioldependent induction of the MPT and is most likely
the protein containing the redox sensor of the pore [23,
24]. However, there remains some controversy regarding
ANT as a primary component of the pore complex [25].
The shorter lagphase preceding diamideinduced
swelling in heart mitochondria from DOXtreated ani
mals suggests a greater degree of oxidized proteins
involved in inducing the MPT pore. Initial swelling rates
were also higher for heart mitochondria from DOXtreat
ed animals. The results suggest increased amounts of oxi
dized thiol residues in proteins of the MPT pore complex
in heart mitochondria from DOXtreated rats, which may
be a relevant factor for the enhanced calciuminduced
MPT detected in those animals. As mentioned above, the
ANT is a primary target for thioldependent regulation of
the MPT pore. In fact, it has previously been demonstrat
ed that decreased functional ANT protein numbers exist
in hearts from DOXtreated animals [7]. The decrease in
mitochondrial antioxidants (such as vitamin E) may also
be relevant because it could contribute to the lack of pro
tection of critical protein thiol groups in the pore com
plex against oxygen free radicals derived from DOX redox
cycling.
State 4 respiration in DOXtreated animals was not
significantly different from saline control, which is con
sistent with previously published results [6]. The higher
ionic strength of the buffer used in these experiments may
explain slight differences with previous reports [12].
Mitochondrial state 3 respiration was significantly
depressed in DOXtreated animals, which again confirms
earlier reports [12]. The novelty in this study was that
DTT and cyclosporin A, when added ex vivo, were inde
pendently able to partially reverse the inhibitory effect of
in vivo DOX treatment on state 3 respiration, indicating
that the inhibition of mitochondrial respiration by DOX
is in part secondary to oxidation of thiol groups and
induction of the MPT, rather than exclusively being a
direct effect of the drug itself. In contrast to DTT, Trolox
did not restore mitochondrial respiration, which can be
explained by a different mechanism of action (unrelated
to specific targeting of thiol groups).
An alternate interpretation of our data is that the oxi
dation of thiol groups occurs secondarily, rather than
causally, to MPT induction, which would explain the
effect of DTT on mitochondrial respiration of DOXtreat
ed animals. Evidence supporting this proposal is the result
obtained by Zhou et al. [7]. The authors demonstrated
that unlike cyclosporin A, DTT is not able to reverse the
decrease in mitochondrial calcium loading capacity in
cardiac mitochondria isolated from DOXtreated rats.
Nevertheless, the lack of inhibition of the MPT by DTT
could also indicate a more permanent alteration of protein
thiol residues in vivo that cannot be reversed by adding
thiol reducing agents ex vivo. The data obtained with
diamide titration suggests that oxidation of thiol residues
occurs in vivo during DOXtreatment and is relevant for
the decreased calcium loading capacity [7, 12].
The fact that both DTT and cyclosporin A, the spe
cific MPT inhibitor [26], were able to partially restore
respiration in cardiac mitochondria isolated from DOX
treated animals suggests that (i) the inhibition of mito
chondrial respiration is secondary to MPT induction and
(ii) DOX reversibly affects one or more proteins associat
ed with oxidative phosphorylation that is also modulated
by its thiol oxidation state. This later proposal is support
ed by the fact that DTT inhibits state 3 respiration in
heart mitochondria from salinetreated rats (Fig. 2b), as
opposed to the partial improvement of respiration
observed in the DOXtreated group. One protein involved
in mitochondrial energy metabolism and whose thiol sta
tus determines its activity is mitochondrial complex I
[27], the activity of which has been shown to be decreased
in DOXtreated rats [12]. The mechanism relating
decreased mitochondrial respiration and MPT alterations
in DOXtreated rats is so far unknown. There are never
theless two likely possibilities. The first is that cyclosporin
A may restore the activity of mitochondria that were pre
viously nonfunctional due to pore opening. Another
hypothesis is that the binding of cyclosporin A to
cyclophilin D [28] may cause the disaggregation of pre
formed pores, thus allowing a crucial component to
again become involved in the oxidative phosphorylation
process.
In conclusion, the results of the current investigation
provide the first evidence that in vivo oxidation of critical
thiol residues in mitochondrial proteins following in vivo
DOX treatment affects both the MPT pore and oxidative
phosphorylation machinery. MPT induction would then
be in part responsible for the observed decrease in mito
chondrial respiration. A particular consequence of DOX
toxicity is that mitochondrial proteins involved in both
oxidative phosphorylation and in the MPT pore complex
may be significantly more susceptible to external stimuli
that would lead to an increase of intracellular oxidative
stress. The results also establish a cause–effect relation
between enhanced MPT activation and decreased mito
chondrial respiration, which is indicated by the partial
restoration of mitochondrial respiration by cyclosporin A,
a potent and specific inhibitor of the MPT. Accordingly,
the MPT may play a so far unknown role in modulating
the adverse bioenergetic and functional consequences
associated with DOX treatment.
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